HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The clinical efficacy of oral tocolytic therapy.

AbstractOBJECTIVE:
Our purpose was to determine whether maintenance oral tocolytic therapy after preterm labor stabilization decreases uterine activity, reduces the rate of recurrent preterm labor and subsequent preterm birth, or improves neonatal outcome.
STUDY DESIGN:
Women with documented idiopathic preterm labor stabilized with acute tocolytic therapy were randomized to three groups: placebo, terbutaline 5 mg, or magnesium chloride 128 mg, all given orally every 4 hours. Patients and providers were blinded to group assignment. All subjects were enrolled in a comprehensive system of preterm birth prevention that included preterm labor education, weekly clinic visits, home uterine contraction assessment, daily phone contact, and 24-hour perinatal nurse access.
RESULTS:
Of the 248 patients who were randomized, 39 were delivered before discharge and 4 were lost to follow-up, leaving 205 for final analysis: 68 placebo, 72 terbutaline, and 65 magnesium. The terbutaline group had significantly more side effects than the placebo group did. All groups had otherwise similar perinatal outcomes when confounding variables were controlled for. Overall, the three groups had a preterm birth rate < 37 weeks of 55.6% delivery, < 34 weeks of 15.6%, a 20.4% rate of newborn intensive care unit admission, and a mean neonatal length of stay of 6.3 days.
CONCLUSIONS:
Maintenance oral tocolytic therapy did not decrease uterine activity, reduce the rate of recurrent preterm labor or preterm birth, or improve perinatal outcome. Overall improvement in perinatal outcome may be achieved with a comprehensive program of preterm birth prevention without the use of maintenance oral tocolytic therapy.
AuthorsO A Rust, J A Bofill, R M Arriola, M E Andrew, J C Morrison
JournalAmerican journal of obstetrics and gynecology (Am J Obstet Gynecol) Vol. 175 Issue 4 Pt 1 Pg. 838-42 (Oct 1996) ISSN: 0002-9378 [Print] United States
PMID8885732 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Tocolytic Agents
  • Magnesium Chloride
  • Terbutaline
Topics
  • Administration, Oral
  • Birth Rate
  • Double-Blind Method
  • Female
  • Hospitalization
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Intensive Care, Neonatal
  • Magnesium Chloride (administration & dosage, therapeutic use)
  • Pregnancy
  • Pregnancy Outcome
  • Terbutaline (administration & dosage, therapeutic use)
  • Tocolytic Agents (administration & dosage, therapeutic use)
  • Treatment Failure
  • Treatment Outcome
  • Uterine Contraction (drug effects)
  • Uterine Monitoring

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: